B-Cell Depletion Therapy Market to Reach USD 62.6 Billion by 2036, Growing at an 8.9% CAGR as Next-Generation Immunotherapy Adoption Accelerates

Future Market Insights forecasts the global B-Cell Depletion Therapy market to grow from $26.7B in 2026 to $62.6B by 2036, implying an 8.9% CAGR. Growth is attributed to rising autoimmune/hematologic disease burden, expanding hospital infusion and specialty pharmacy capacity, and broader regulatory approvals, with Anti-CD20 monoclonal antibodies (70% share) and autoimmune diseases (60% share) leading demand. India is expected to grow fastest at 11.2% CAGR as adoption and healthcare infrastructure improve.

Analysis

This is a slow-burn demand signal, not a near-term catalyst. The economic upside accrues less to the molecule owners and more to the channel layer: specialty distribution, infusion throughput, and reimbursement optimization. In other words, the market may keep growing while manufacturer net pricing gets steadily tougher as biosimilars, step-edits, and site-of-care migration cap margin upside.

Among large caps, the cleanest read-through is to firms with direct anti-CD20 exposure and subcutaneous convenience, while more diversified immunology franchises likely see only modest portfolio benefit. The bigger second-order winner set is outside the headline names: distributors and hospital systems that can monetize recurring administration and monitoring, especially if infusion volume rises faster than site-of-care shifts to home settings.

The contrarian risk is that the market is over-rotating from TAM expansion to EPS impact. This kind of report usually confirms a trend that is already visible in prescriptions and guidelines; the real test is whether payer coverage and real-world persistence improve enough to offset price compression. Over 1-3 quarters, watch for any tightening in prior auth or safety commentary; over 6-18 months, the key falsifier is biosimilar share pressure without offsetting volume acceleration.

Key Decisions for Investors

• Long COR / short XBI over 6-12 months: best risk-reward if chronic biologic utilization expands faster than margin compression. Falsify if specialty-drug price pressure overwhelms volume growth.
• Relative value: long NVS / short BIIB into the next 1-2 earnings cycles. NVS has cleaner direct exposure to anti-CD20 demand and convenience-driven share gain; BIIB is more exposed to the possibility that this is a mature-share story rather than incremental upside.
• Buy HCA or UHS on pullbacks over the next 1-3 months as an operational beneficiary of infusion-capacity expansion, but keep sizing modest; thesis breaks if labor and reimbursement costs outpace utilization.
• Do not chase GSK or JNJ on this headline alone. Wait for specific evidence of autoimmune share gain, label expansion, or management commentary before adding exposure.